Announcements Trials
Browse Landscape

Phase

Phase 2/3 3Phase 2 2

Status

Recruiting 5

Sponsor Class

INDUSTRY 115OTHER 92NIH 25OTHER_GOV 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Breast 2Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1HER-2 Negative Breast Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Bevacizumab 5Capecitabine 3toripalimab 2olaparib 2durvalumab 2darolutamide 2atezolizumab 2apatinib 2anlotinib 2Standard of Care 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Laparoscopy 2Immunotherapy 2Fluorouracil 2Drug Therapy 2130-nm albumin-bound paclitaxel 2trametinib 1spartalizumab 1pyrotinib 1pomalidomide 1palbociclib 1nilotinib 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1irinotecan sucrosofate 1hetrombopag 1glasdegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER_GOV × Bevacizumab × 90 days × Clear all
NCT07472153 2026-05-28

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05398861 2026-04-16

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
79 enrolled
Breast

HER-2 Negative Breast Cancer

NCT07293468 2026-04-09

BIIRTH

Tuen Mun Hospital

Phase 2/3 Recruiting
106 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Henan Cancer Hospital

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡